FDA Approves Hovilpri for Resistant HSV in Immunocompromised Patients

Key Facts

1The US FDA has granted approval for Hovilpri to treat resistant Herpes Simplex Virus (HSV) in immunocompromised patients.

The US Food and Drug Administration (FDA) has granted approval for Hovilpri to treat resistant Herpes Simplex Virus (HSV) in immunocompromised patients. Investing.com reported that the approval aims to provide a treatment option for patients whose viral strains do not respond to standard therapies.

This regulatory milestone targets specific viral strains that have developed resistance to conventional treatments. The approval follows recent global economic data, including the US ISM Services PMI which was reported at 54.9 on October 5, 2026.